• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Ionis reports fourth quarter and full year 2022 financial results

    2/22/23 7:01:00 AM ET
    $IONS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IONS alert in real time by email

    Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU

    Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expanding with two new Phase 3 programs

    Ionis provides full year 2023 financial guidance

    CARLSBAD, Calif., Feb. 22, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), a genetic medicines company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial results are summarized below:

    Ionis logo with tagline (PRNewsfoto/Ionis Pharmaceuticals, Inc.)





    Three months ended

    December 31,



    Year ended

    December 31,





    2022



    2021



    2022



    2021





    (amounts in millions)



    Total revenue



    $152



    $440



    $587



    $810



    Operating expenses



    $360



    $219



    $998



    $840



    Operating expenses on a non-GAAP basis



    $335



    $196



    $898



    $695



    Net (loss) income



    ($52)



    $225



    ($270)



    ($29)



    Net (loss) income on a non-GAAP basis



    ($168)



    $248



    ($311)



    $116



    Cash, cash equivalents and short-term investments1











    $1,987



    $2,115











































    1  Balance at December 31, 2022 does not include $500 million received in January 2023 under royalty monetization transaction.

    Financial Highlights

    • 2022 revenue was in line with expectations, reflecting revenue from numerous diverse sources. The prior year fourth quarter and full year benefited from the $200 million earned from AstraZeneca to jointly develop and commercialize eplontersen
    • 2022 operating expenses increased as planned compared to the prior year, reflecting investments in pipeline, technology and go-to-market activities for eplontersen, olezarsen and donidalorsen
    • Further strengthened financial position with royalty monetization and sale and leaseback transactions worth up to $1.5 billion, including more than $700 million already received
    • Initiated construction of a new manufacturing facility to support Ionis' goal to sustainably deliver genetic medicines to the market

    Recent Late-Stage Pipeline Highlights

    • Submitted the eplontersen NDA in the U.S. for patients with polyneuropathy caused by hereditary TTR amyloidosis
    • FDA Advisory Committee meeting planned for March 22, 2023 to review Biogen's NDA for tofersen for patients with SOD1-ALS (PDUFA date of April 25, 2023); EMA accepted MAA for review
    • FDA granted olezarsen Fast Track designation for the treatment of patients with FCS
    • Reported positive Phase 2 data from the open label extension study of donidalorsen in patients with hereditary angioedema treated for one year, including new data showing clinically meaningful improvement in angioedema quality of life score; Phase 3 study expected to complete enrollment in 2023
    • GSK advanced bepirovirsen into Phase 3 development in patients with chronic hepatitis B

    Recent Additional Pipeline Highlights

    • Biogen initiated a Phase 2 study of IONIS-MAPTRx (BIIB080) in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease
    • Roche initiated a Phase 2 study of tominersen in patients with prodromal or early manifest Huntington's disease
    • Biogen initiated a Phase 1 study of ION306 (BIIB115) for the treatment of spinal muscular atrophy with the potential for long interval dosing

    Recent Technology Advancement Highlights

    • Partnered with Metagenomi to add gene editing capabilities to Ionis' technology platform
    • Advanced programs incorporating muscle LICA technology and MsPA backbone chemistry into preclinical development

    "We made substantial progress in 2022, marked by important achievements, including the December submission of the eplontersen NDA for people with ATTRv-PN. We also delivered multiple positive data readouts, enabling us to advance and expand our rich late- and mid-stage pipeline. And we took important steps to expand and diversify our technology, including our Metagenomi collaboration to add DNA editing to our platform," said Brett P. Monia, Ph.D., chief executive officer of Ionis. "As we start 2023, we are positioned to build upon our achievements by bringing our first near-term commercial opportunities to the market. We look forward to reporting the 66-week results from the eplontersen NEURO-TTRansform study in the first half of this year. Importantly, we are prepared to co-commercialization eplontersen with our partner, AstraZeneca. We also look forward to Phase 3 data from olezarsen in FCS patients, positioning us for our first independent launch. With the talent and resources we have today, we anticipate a highly productive year that will enable us to drive increasing value for all stakeholders."

    Fourth Quarter and Full Year 2022 Financial Results

    Revenue

    Ionis' revenue was comprised of the following:





    Three months ended



    Year ended







    December 31,



    December 31,







    2022



    2021



    2022



    2021



    Revenue:



    (amounts in millions)



         Commercial revenue:



















    SPINRAZA royalties



    $67



    $69



    $242



    $268



    TEGSEDI and WAYLIVRA revenue, net



    7



    9



    30



    56



    Licensing and royalty revenue



    6



    9



    31



    18



    Total commercial revenue



    80



    87



    303



    342



    Research and development revenue:



















    Amortization from upfront payments



    15



    21



    69



    78



    Milestone payments



    14



    40



    74



    88



    License fees



    -



    290



    37



    291



    Other services



    22



    2



    27



    11



    Collaborative agreement revenue



    51



    353



    207



    468



    Eplontersen joint development revenue



    21



    -



    77



    -



    Total research and development revenue



    72



    353



    284



    468



    Total revenue



    $152



    $440



    $587



    $810















    Ionis' 2022 revenue continued to be derived from diverse sources, with just over half coming from commercial products and the balance from numerous partnered programs. SPINRAZA royalties, the largest contributor to the Company's commercial revenue, increased each quarter in 2022. Total SPINRAZA product sales increased six percent in the fourth quarter of 2022 compared to the prior quarter and also increased four percent compared to the same quarter in 2021. The increases were driven by stabilization in the U.S. and growth in Asian markets partially offset by competition in Europe. Total SPINRAZA product sales decreased six percent year-over-year due to foreign currency exchange and competition in Europe. TEGSEDI and WAYLIVRA revenue in 2022 reflected the shift to distribution fees.

    R&D revenue for 2022 included $112 million from Biogen for advancing several neurology disease programs, $77 million from AstraZeneca for its share of the global Phase 3 development costs for eplontersen and $64 million from Roche for licensing and advancing IONIS-FB-LRx, among other partner payments. R&D revenue was higher in 2021 compared to 2022 primarily due to the $200 million Ionis earned in the fourth quarter of 2021 from AstraZeneca to jointly develop and commercialize eplontersen.

    Operating Expenses

    Ionis' operating expenses increased for the three months and year ended December 31, 2022 compared to the same periods in 2021, in line with expectations. For both periods, higher R&D expenses were driven by the increased number of Phase 3 studies the Company is conducting, which doubled from three to six studies in 2021, and the $80 million upfront payment for Ionis' collaboration with Metagenomi. SG&A expenses increased for the three months ended December 31, 2022 compared to the same period in 2021 driven by Ionis' go-to-market activities for eplontersen, olezarsen and donidalorsen. SG&A expenses were lower for 2022 compared to 2021 largely due to the substantial savings the Company achieved from integrating Akcea and restructuring the Company's commercial operations in 2021.

    Gain on Sale of Property and Related Tax Impact

    In October 2022, Ionis entered into a sale and leaseback transaction for several of its real estate assets. Under the agreement, Ionis received net proceeds of $200 million, with the potential to receive additional payments of up to $40 million plus funding to expand the Company's R&D campus. As a result, the Company recognized a $150 million gain on sale of property and $9 million in related income tax expense in the fourth quarter of 2022. In conjunction with the sale and leaseback transaction, the Company extinguished its mortgage debt for the related properties and recorded a new right of lease asset and liability on its balance sheet.

    Balance Sheet

    As of December 31, 2022, Ionis had cash, cash equivalents and short-term investments of $2.0 billion compared to $2.1 billion at December 31, 2021. Ionis' year-end cash balance does not include the $500 million the Company received from Royalty Pharma in January 2023. From December 31, 2021 to December 31, 2022, Ionis' debt obligations decreased by $50 million because the Company repaid its mortgage debt and Ionis' working capital decreased modestly driven by the Company's slightly lower cash and short-term investments balance.

    2023 Financial Guidance

    The Company's 2023 guidance reflects its ability to earn substantial revenue from its commercial portfolio and partnered programs. It also reflects the Company's commitment to investing in advancing its rich late-stage pipeline and preparing to commercialize its near-term commercial opportunities, eplontersen, olezarsen and donidalorsen, while maintaining a healthy balance sheet to continue investing for future growth.

     

    Full Year 2023 Guidance









    Revenue



    >$575 million





    Operating expenses on a non-GAAP basis



    ~$970 - $995 million





    Net operating loss on a non-GAAP basis



    <$425 million





    Cash, cash equivalents and short-term investments



    ~$2.0 billion





    "Our solid 2022 financial results reflected our ability to earn substantial revenues while investing in key programs with the potential to drive substantial future growth, including our near-term commercial opportunities," said Elizabeth L. Hougen, chief financial officer of Ionis. "Additionally, we recently bolstered our balance sheet with more than $700 million from our royalty monetization and sale and leaseback transactions. With approximately $2.5 billion in pro forma cash, we have the resources to continue to advance our innovative pipeline and achieve commercial readiness for eplontersen, olezarsen and donidalorsen."

    Webcast

    Management will host a conference call and webcast to discuss Ionis' fourth quarter and full year 2022 results at 11:30 a.m. Eastern time on Wednesday, February 22, 2022. Interested parties may access the webcast here. A webcast replay will be available for a limited time at the same address. To access the Company's fourth quarter and full year 2022 earnings slides click here.

    About Ionis Pharmaceuticals, Inc.

    For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.    

    To learn more about Ionis visit www.ionispharma.com or follow us on Twitter @ionispharma.

    Ionis' Forward-looking Statement

    This press release includes forward-looking statements regarding Ionis' business, financial guidance and the therapeutic and commercial potential of SPINRAZA (nusinersen), TEGSEDI (inotersen), WAYLIVRA (volanesorsen), eplontersen, olezarsen, donidalorsen, ION363, tofersen, pelacarsen, bepirovirsen, Ionis' technologies and Ionis' other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2021, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.

    In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.

    Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics® is a registered trademark of Akcea Therapeutics, Inc. TEGSEDI® is a registered trademark of Akcea Therapeutics, Inc. WAYLIVRA® is a registered trademark of Akcea Therapeutics, Inc. SPINRAZA® is a registered trademark of Biogen.

     

    IONIS PHARMACEUTICALS, INC.

    SELECTED FINANCIAL INFORMATION

    Condensed Consolidated Statements of Operations

    (In Millions, Except Per Share Data)







    Three months ended,



    Year ended





    December 31,



    December 31,





    2022



    2021



    2022



    2021





    (unaudited)









    Revenue:

















         Commercial revenue:

















    SPINRAZA royalties



    $67



    $69



    $242



    $268

    TEGSEDI and WAYLIVRA revenue, net



    7



    9



    30



    56

    Licensing and royalty revenue



    6



    9



    31



    18

    Total commercial revenue



    80



    87



    303



    342

    Research and development revenue:

















    Collaborative agreement revenue



    51



    353



    207



    468

    Eplontersen joint development revenue



    21



    -



    77



    -

    Total research and development revenue



    72



    353



    284



    468

    Total revenue



    152



    440



    587



    810

    Expenses:

















           Cost of sales



    4



    2



    14



    11

        Research, development and patent



    308



    179



    833



    643

        Selling, general and administrative





    48



    38



    151



    186

    Total operating expenses



    360



    219



    998



    840

    Income (loss) from operations



    (208)



    221



    (411)



    (30)



















    Other income (expense):

















    Gain on sale of real estate assets



    150



    -



    150



    -

    Other income, net



    14



    4



    3



    -

    Income (loss) before income tax benefit (expense)



    (44)



    225



    (258)



    (30)



















    Income tax benefit (expense)



    (8)



    -



    (12)



    1



















    Net income (loss)



    ($52)



    $225



    ($270)



    ($29)



















    Basic net income (loss) per share



    ($0.37)



    $1.59



    ($1.90)



    ($0.20)

    Diluted net income (loss) per share



    ($0.37)



    $1.41



    ($1.90)



    ($0.20)

    Shares used in computing basic net income (loss) per share



    142



    141



    142



    141

    Shares used in computing diluted net income (loss) per share



    142



    160



    142



    141



























     

    IONIS PHARMACEUTICALS, INC.

    Reconciliation of GAAP to Non-GAAP Basis:

    Condensed Consolidated Operating Expenses, Income (Loss) From Operations, and Net Income (Loss)

    (In Millions)







    Three months ended

    December 31,



    Year ended

    December 31,





    2022



    2021



    2022



    2021





    (unaudited)

    As reported research, development and patent expenses according to GAAP



    $308



    $179



    $833



    $643

        Excluding compensation expense related to equity awards      



    (19)



    (16)



    (74)



    (88)

        Excluding Akcea merger and restructured commercial operation costs*      



    -



    (1)



    -



    (9)

    Non-GAAP research, development and patent expenses



    $289



    $162



    $759



    $546



















     

    As reported selling, general and administrative expenses according to GAAP



    $48



    $38



    $151



    $186

        Excluding compensation expense related to equity awards      



    (7)



    (7)



    (26)



    (33)

        Excluding Akcea merger and restructured commercial operation costs*      



    -



    1



    -



    (15)

    Non-GAAP selling, general and administrative expenses



    $41



    $32



    $125



    $138



















    As reported operating expenses according to GAAP



    $360



    $219



    $998



    $840

    Excluding compensation expense related to equity awards      



    (25)



    (23)



    (100)



    (121)

    Excluding Akcea merger and restructured commercial operation costs*      



    -



    -



    -



    (24)

    Non-GAAP operating expenses



    $335



    $196



    $898



    $695



















    As reported income (loss) from operations according to GAAP



    ($208)



    $221



    ($411)



    ($30)

        Excluding compensation expense related to equity awards      



    (25)



    (23)



    (100)



    (121)

        Excluding Akcea merger and restructured commercial operation costs*      



    -



    -



    -



    (24)

    Non-GAAP income (loss) from operations



    ($183)



    $244



    ($311)



    $115



















    As reported net income (loss) according to GAAP



    ($52)



    $225



    ($270)



    ($29)

        Excluding compensation expense related to equity awards      



    (25)



    (23)



    (100)



    (121)

        Excluding Akcea merger and restructured commercial operation costs*      



    -



    -



    -



    (24)

        Excluding gain on sale of real estate assets**



    150



    -



    150



    -

        Excluding income tax effect related to gain on sale of real estate assets



    (9)



    -



    (9)



    -

    Non-GAAP net income (loss)



    ($168)



    $248



    ($311)



    $116



    *In October 2020, Ionis completed a merger transaction with Akcea such that following the completion of the merger Akcea became a wholly owned subsidiary of Ionis. Additionally, in December 2020 and April 2021, Ionis restructured its European operations and its North American TEGSEDI operations, respectively, as a result of entering into distribution agreements with Sobi. The Company excluded the Akcea merger and restructured commercial operation costs from its non-GAAP amounts for the applicable periods.



    **In October 2022, Ionis entered into a sale and leaseback transaction for several of its real estate assets. As a result, the Company recognized a $150 million gain on sale of real estate assets in the fourth quarter of 2022. The Company excluded the gain on sale of real estate assets and the related tax effect from its non-GAAP amounts for the applicable periods.

    Reconciliation of GAAP to Non-GAAP Basis

    As illustrated in the Selected Financial Information in this press release, non-GAAP operating expenses, non-GAAP income (loss) from operations, and non-GAAP net income (loss) were adjusted from GAAP to exclude compensation expense related to equity awards and the related tax effects. Compensation expense related to equity awards are non-cash. In 2022 Ionis' non-GAAP net loss excluded the gain on property related to the sale and leaseback transaction and the related tax effect. In 2021 all non-GAAP amounts also excluded expenses related to the Akcea merger and restructured commercial operations. Expenses related to the Akcea merger and restructured commercial operations included: severance costs, retention costs and other costs related to commercial operations. Ionis has regularly reported non-GAAP measures for operating results as non-GAAP results. These measures are provided as supplementary information and are not a substitute for financial measures calculated in accordance with GAAP. Ionis reports these non-GAAP results to better enable financial statement users to assess and compare its historical performance and project its future operating results and cash flows. Further, the presentation of Ionis' non-GAAP results is consistent with how Ionis' management internally evaluates the performance of its operations.

    IONIS PHARMACEUTICALS, INC.

    Summary of the Financial Impacts of the Eplontersen Collaboration with AstraZeneca

    For the Year Ended, December 31, 2022

    (Unaudited)

     



    Collaboration

    Activities



    Financial

    Statement Line



    Impact of Cost-Sharing Provisions

    on Ionis' Statement of Operations















    Phase 3 Development:

    Ionis leads and conducts



    Eplontersen Joint

    Development

    Revenue

    (R&D Revenue)



    $77M



    55% of Total Phase 3

    development expenses,

    including

    internal+external costs &

    CMC costs, net of Ionis'

    share of AstraZeneca's

    Phase 3 development

    expenses















    Development

    Expenses

    (R&D Expenses)



    $147M



    100% of Ionis' Phase 3

    development expenses

    Ionis' financial results for the year ended December 31, 2022 reflected the cost-sharing provisions related to its collaboration with AstraZeneca to develop and commercialize eplontersen for the treatment of ATTR. Under the terms of the collaboration agreement, AstraZeneca is currently paying 55 percent of the costs associated with the ongoing global Phase 3 development program. Because Ionis is leading and conducting the Phase 3 development program, Ionis is recognizing the 55 percent of cost-share funding AstraZeneca is responsible for, net of Ionis' share of AstraZeneca's development expenses, as R&D revenue in the same period Ionis incurs the related development expenses. For the year ended December 31, 2022 Ionis earned $77 million in joint development revenue under this collaboration.

    Because AstraZeneca is responsible for the majority of the medical affairs and commercial costs in the U.S. and all costs associated with commercializing eplontersen outside the U.S., Ionis is recognizing cost-share funding it receives from AstraZeneca related to these activities as a reduction of its medical affairs (R&D expenses) and commercialization expenses (SG&A expenses). For the year ended December 31, 2022 Ionis recognized $2.0 million and $2.6 million of medical affairs expenses and commercialization expenses for eplontersen, respectively, net of cost-share funding from AstraZeneca. Ionis expects its medical affairs and commercialization expenses to increase as this collaboration progresses.

    IONIS PHARMACEUTICALS, INC.

    Condensed Consolidated Balance Sheets

    (In Millions)

















    December 31,



    December 31,







    2022



    2021







    (unaudited)







    Assets:











      Cash, cash equivalents and short-term investments



    $1,987



    $2,115



      Contracts receivable



    26



    62



      Other current assets



    190



    168



      Property, plant and equipment, net



    74



    178



      Right-of-use assets



    182



    18



      Other assets



    75



    71



         Total assets



    $2,534



    $2,612















    Liabilities and stockholders' equity:











      Other current liabilities



    $221



    $143



      Current portion of deferred contract revenue



    91



    98



      0% convertible senior notes, net



    622



    619



      0.125% convertible senior notes, net



    545



    542



      Long-term lease liabilities



    178



    19



      Long-term obligations, less current portion



    16



    67



      Long-term deferred contract revenue



    288



    352



      Total stockholders' equity



    573



    772



        Total liabilities and stockholders' equity



    $2,534



    $2,612



















     

    2023 Key Value Driving Events(1) 

    Regulatory Actions

    Program

    Indication

    Regulatory Action

    Tofersen

    SOD1-ALS

    NDA approval

    EU approval

    Eplontersen (TTR)

    ATTRv polyneuropathy

    NDA approval

    OUS filings



    Key Clinical Achievements

    Program

    Indication

    Event

    Eplontersen (TTR)

    ATTRv polyneuropathy

    Phase 3 data (week 35 & 66)

    Olezarsen

    FCS

    Phase 3 data

    Eplontersen (TTR)

    ATTR cardiomyopathy

    Phase 3 full enrollment

    Donidalorsen (PKK)

    HAE

    Phase 3 full enrollment



    Phase 3 Initiations

    Program

    Indication

    Timing

    Bepirovirsen (HBV)

    Hepatitis B virus infection

    H1:23 (achieved)

    IONIS-FB-LRx

    Immunoglobulin A nephropathy

    H1:23



    (1)  Timing expectations based on current assumptions and subject to change.

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ionis-reports-fourth-quarter-and-full-year-2022-financial-results-301752630.html

    SOURCE Ionis Pharmaceuticals, Inc.

    Get the next $IONS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IONS

    DatePrice TargetRatingAnalyst
    4/7/2025$45.00Buy
    H.C. Wainwright
    3/31/2025$39.00Neutral
    Redburn Atlantic
    8/2/2024$67.00 → $60.00Outperform → Market Perform
    BMO Capital Markets
    7/24/2024$53.00 → $62.00Market Perform → Outperform
    Leerink Partners
    7/16/2024$29.00 → $75.00Buy
    Jefferies
    6/14/2024$44.00Underperform → Mkt Perform
    Bernstein
    4/10/2024$58.00Peer Perform → Outperform
    Wolfe Research
    1/2/2024$52.00 → $62.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $IONS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Corp and Development Ops Birchler Brian converted options into 1,875 shares and sold $19,292 worth of shares (680 units at $28.37), increasing direct ownership by 2% to 56,660 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      4/17/25 4:53:27 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Chf GL Pdt Str Ofcr Jenne Kyle sold $85,534 worth of shares (3,016 units at $28.36) and converted options into 12,226 shares, increasing direct ownership by 463% to 11,199 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      4/17/25 4:53:18 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Ionis Pharma with a new price target

      H.C. Wainwright initiated coverage of Ionis Pharma with a rating of Buy and set a new price target of $45.00

      4/7/25 8:43:57 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Redburn Atlantic initiated coverage on Ionis Pharma with a new price target

      Redburn Atlantic initiated coverage of Ionis Pharma with a rating of Neutral and set a new price target of $39.00

      3/31/25 8:13:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharma downgraded by BMO Capital Markets with a new price target

      BMO Capital Markets downgraded Ionis Pharma from Outperform to Market Perform and set a new price target of $60.00 from $67.00 previously

      8/2/24 7:32:04 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ionis to host 2025 virtual Annual Meeting of Stockholders

      Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2025 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 5, 2025. The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET (2:00 p.m. – 2:15 p.m. PT) – Virtual Annual Meeting of Stockholders All stockholders of record at the close of business on April 7, 2025, are invited to participate in the virtual Annual Meeting webcast, which will be broadcast live at www.virtualshareholdermeeting.com/IONS2025. Stockholders of record will receive an official proxy card from their brokerage firm. Each proxy card contains a 16-digit control number required

      5/6/25 7:05:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event

      BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, hosted a virtual investor event on its clinical programs in developmental and epileptic encephalopathies (DEEs) on Friday, May 2, 2025. "We were excited to highlight the significant opportunity in DEEs and progress Praxis is making in this field," said Marcio Souza, president and chief executive officer of Praxis. "Relutrigine continues to show tremendous promise to broadly address the DEE market

      5/5/25 8:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 8:34:57 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Ionis Pharmaceuticals Inc.

      SC 13G/A - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/14/24 1:28:29 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Ionis Pharmaceuticals Inc.

      SC 13G - IONIS PHARMACEUTICALS INC (0000874015) (Subject)

      11/8/24 10:52:38 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ionis Pharmaceuticals Inc.

      10-Q - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/30/25 3:56:17 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/30/25 11:15:21 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Ionis Pharmaceuticals Inc.

      DEFA14A - IONIS PHARMACEUTICALS INC (0000874015) (Filer)

      4/25/25 4:26:13 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IONS
    Leadership Updates

    Live Leadership Updates

    See more

    $IONS
    Financials

    Live finance-specific insights

    See more

    $IONS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Alltrna Announces Updates to Its Board of Directors

      Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

      7/17/24 8:00:00 AM ET
      $APRE
      $CYTK
      $EVLO
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

      Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

      6/24/24 4:05:00 PM ET
      $CTNM
      $IONS
      $NVS
      $RNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
      Medicinal Chemicals and Botanical Products
    • Ionis announces the appointment of Michael Yang to Board of Directors

      CARLSBAD, Calif., Dec. 14, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Michael Yang, an experienced biopharmaceutical executive, to the Ionis Board of Directors. Mr. Yang's appointment expands the total number of Ionis Board members to 10. Mr. Yang has more than 20 years of broad senior level leadership experience in biotech, pharmaceutical and medical device companies, where he launched new platforms, expanded global revenues and diversified product lines. He most recently served as President, Chief Executive Officer and B

      12/14/23 4:05:00 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports first quarter 2025 financial results

      - Encouraging start to first independent launch with TRYNGOLZATM - - On track for second independent launch with donidalorsen PDUFA August 21, 2025 - - Increasing 2025 financial guidance by more than 20% - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company") today reported financial results for the first quarter ended March 31, 2025. "With an encouraging start to the TRYNGOLZA launch for familial chylomicronemia syndrome, the first of four independent launches expected over the next two years, Ionis' new chapter as a fully integrated, commercial-stage biotechnology company is well underway," said Brett P. Monia, Ph.D., chief executive officer, Ionis. "We look forward to continued m

      4/30/25 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results

      Up to four programs in registrational phase by 2025 Planned interim analysis for ulixacaltamide Essential3 Study 1 to be conducted in Q4 2024 Topline results for Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) expected in Q3 2024 PRAX-628 Phase 2/3 POWER1 study to initiate in Q4 2024 Initiation of additional Phase 2 study (RADIANT) for PRAX-628 in focal and generalized epilepsy in 2H 2024, with topline results expected in 1H 2025 Cash and investments of $434 million as of June 30, 2024, maintains runway into 2027 BOSTON, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a

      8/13/24 7:00:00 AM ET
      $IONS
      $PRAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ionis reports second quarter 2024 financial results

      WAINUATM U.S. launch progressing well; approved in Canada; EU approval decision expected this year Olezarsen PDUFA December 19, 2024 for FCS Positive Phase 3 donidalorsen data for HAE; preparing U.S. and EU regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif., Aug. 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) (the "Company"), today reported financial results for the second quarter of 2024. "Over the first half of this year, we continued to deliver on our goal to bring a steady cadence of medicines to people with serious dise

      8/1/24 7:00:00 AM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      5/2/25 4:38:26 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Hayden Michael R bought $181,079 worth of shares (5,000 units at $36.22), increasing direct ownership by 17% to 35,219 units (SEC Form 4)

      4 - IONIS PHARMACEUTICALS INC (0000874015) (Issuer)

      12/26/24 4:57:52 PM ET
      $IONS
      Biotechnology: Pharmaceutical Preparations
      Health Care